Clinical Validation of Companion Diagnostics for the Selection of Patients with Non–Small Cell Lung Cancer Tumors Harboring Epidermal Growth Factor Receptor Exon 20 Insertion Mutations for Treatment with Amivantamab

Jatkoe, Tim; Wang, Songbai; Odegaard, Justin I.; Roth, Anne Marie Velasco; Osgood, Drew; Martı́nez, G.; Lucas, Paul L.; Curtin, Joshua C.; Karkera, Jayaprakash D.

doi:10.1016/j.jmoldx.2022.07.003

Cited by 5 publications

(2 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Amivantamab is a novel, fully humanized IgG1 bispecific antibody targeting both EGFR and Met, with multiple mechanisms of action for treating EGFR and Met-driven diseases ( 7 , 15 , 25 – 27 , 55 , 61 ). It inhibits ligand-induced activation by blocking ligand-receptor binding, degrades receptor-antibody complexes to render them inactive, and induces Fc-effector molecule-mediated cytotoxicity for tumor cell elimination ( 21 ).…”

Section: Treatment Of Egfr Ex20insmentioning

confidence: 99%

The current landscape, advancements, and prospects in the treatment of patients with EGFR exon 20 insertion mutations warrant scientific elucidation

Man,

Sun,

Chen

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

Epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins) mutations are the third most prevalent mutation in non-small cell lung cancer (NSCLC), following the 19del and L858R mutations. The unique nature of the EGFR ex20ins mutation poses challenges for the effectiveness of first- and second-generation EGFR tyrosine kinase inhibitors (TKIs). As a result, chemotherapy remains the primary and more effective treatment approach. However, with advancements in time and technology, numerous experimental studies have revealed the potential of novel drugs and therapies to have stronger inhibitory effects on EGFR ex20ins mutations. In this comprehensive review, we provide an overview of the current treatment landscape, recent advancements, and the prospects for patients with advanced NSCLC characterized by EGFR ex20ins mutations.

show abstract

Section: Treatment Of Egfr Ex20insmentioning

confidence: 99%

The current landscape, advancements, and prospects in the treatment of patients with EGFR exon 20 insertion mutations warrant scientific elucidation

Man,

Sun,

Chen

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…HER2-low expression in mBC is dynamic between primary tumours and tumours in the advanced setting. [58][59][60] Repeat biomarker testing on tumours obtained in the advanced setting has also been recommended to assist with identifying optimal treatment options for mBC. 40 The ultimate decision is probably best informed after discussion with the patient's treating physician.…”

Section: Practical Considerations Of When To Seek Consensusmentioning

confidence: 99%

Best practices for achieving consensus in HER2‐low expression in breast cancer: current perspectives from practising pathologists

Tozbikian,

Bui,

Hicks

et al. 2024

Histopathology

View full text Add to dashboard Cite

AimsHuman epidermal growth factor receptor 2 (HER2) expression is an important biomarker in breast cancer (BC). Most BC cases categorised as HER2‐negative (HER2−) express low levels of HER2 [immunohistochemistry (IHC) 1+ or IHC 2+/in‐situ hybridisation not amplified (ISH−)] and represent a clinically relevant therapeutic category that is amenable to targeted therapy using a recently approved HER2‐directed antibody–drug conjugate. A group of practising pathologists, with expertise in breast pathology and BC biomarker testing, outline best practices and guidance for achieving consensus in HER2 IHC scoring for BC.Methods and resultsThe authors describe current knowledge and challenges of IHC testing and scoring of HER2‐low expressing BC and provide best practices and guidance for accurate identification of BCs expressing low levels of HER2. These expert pathologists propose an algorithm for assessing HER2 expression with validated IHC assays and incorporate the 2023 American Society of Clinical Oncology and College of American Pathologist guideline update. The authors also provide guidance on when to seek consensus for HER2 IHC scoring, how to incorporate HER2‐low into IHC reporting and present examples of HER2 IHC staining, including challenging cases.ConclusionsAwareness of BC cases that are negative for HER protein overexpression/gene amplification and the related clinical relevance for targeted therapy highlight the importance of accurate HER2 IHC scoring for optimal treatment selection.

show abstract

Distribution and Detectability of EGFR Exon 20 Insertion Variants in NSCLC

Ou¹,

Hong²,

Christopoulos³

et al. 2023

Journal of Thoracic Oncology

View full text Add to dashboard Cite

Clinical Validation of Companion Diagnostics for the Selection of Patients with Non–Small Cell Lung Cancer Tumors Harboring Epidermal Growth Factor Receptor Exon 20 Insertion Mutations for Treatment with Amivantamab

Cited by 5 publications

References 29 publications

The current landscape, advancements, and prospects in the treatment of patients with EGFR exon 20 insertion mutations warrant scientific elucidation

The current landscape, advancements, and prospects in the treatment of patients with EGFR exon 20 insertion mutations warrant scientific elucidation

Best practices for achieving consensus in HER2‐low expression in breast cancer: current perspectives from practising pathologists

Distribution and Detectability of EGFR Exon 20 Insertion Variants in NSCLC

Contact Info

Product

Resources

About